Statement: neurula is an stage in embryonic development during which neurulation takes place, and which follows the gastrula stage. the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response .
Primary_evidence: Outcome Measurement:    Objective Response Rate (ORR)   An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response.   Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization   Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008) Results 1:    Arm/Group Title: Fulvestrant 250 mg   Arm/Group Description: Fulvestrant 250 mg   Overall Number of Participants Analyzed: 45   Measure Type: Number   Unit of Measure: percentage of participants  11.1 Results 2:    Arm/Group Title: Fulvestrant 250 mg + Loading Dose   Arm/Group Description: Fulvestrant 250 mg + Loading Dose   Overall Number of Participants Analyzed: 51   Measure Type: Number   Unit of Measure: percentage of participants  17.6
Secondary_evidence: Outcome Measurement:    Objective Response (OR)   OR is defined as complete response (CR) and partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST). OR was primary endpoint only for Cohort B.   Time frame: Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter. Results 1:    Arm/Group Title: Cohort B   Arm/Group Description: Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd   Overall Number of Participants Analyzed: 21   Measure Type: Number   Unit of Measure: Participants with OR  0